Actuate Therapeutics
ACTU
25 hedge funds and large institutions have $70.4M invested in Actuate Therapeutics in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1,359% more capital inflows, than outflows
Capital inflows: $2.46M | Capital outflows: $169K
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
32% more funds holding
Funds holding: 19 → 25 (+6)
1.46% more ownership
Funds ownership: 51.8% → 53.26% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voss Capital
Houston,
Texas
|
+$700K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$432K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$382K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$146K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$84.2K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$83.3K |
| 3 |
BlackRock
New York
|
-$1.18K |
| 4 |
JP Morgan Chase
New York
|
-$24 |
ACTU Hedge Fund Activity: Q1 2025 in Review
25 of the 7,481 institutional investors tracked by Wall St. Rank reported a position in Actuate Therapeutics (ACTU) for Q1 2025, worth a combined $70.4M — down 13% from $80.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ACTU positions and 3 closed out — a net gain of 6 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was Voss Capital, adding an estimated $700K. The largest seller was OMERS Administration Corp, exiting entirely with an estimated $84.2K sold.
- 25 institutional investors held Actuate Therapeutics (ACTU) as of Q1 2025, up from 19 in Q4 2024.
- Funds reported $70.4M of Actuate Therapeutics stock for Q1 2025, down 13% quarter-over-quarter.
- 9 funds opened new Actuate Therapeutics positions in Q1 2025 and 3 closed out, a net change of +6 holders.
- The largest Actuate Therapeutics buyer in Q1 2025 was Voss Capital, an estimated $700K added.
- The largest Actuate Therapeutics seller in Q1 2025 was OMERS Administration Corp, an estimated $84.2K sold.
Based on aggregated 13F filings for Q1 2025.